Auro Laboratories Limited will convene a board meeting on Friday, May 29, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The meeting will also review the report of the auditors accompanying these results. This disclosure is significant as it will provide the final financial performance metrics for the fiscal year, determining the company's profitability and operational status for FY26.

The board will also address any other matters with the permission of the Chair. The intimation was submitted under Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In compliance with the Company's Code of Conduct to Regulate, Monitor and Report trading by Designated Persons and Immediate Relatives of Designated Persons, the trading window for dealing in the securities of the company has been closed since April 01, 2026. The window will remain shut until 48 hours after the financial results are announced to the stock exchange.

The filing was signed by Siddhartha Deorah, Whole Time Director of Auro Laboratories Limited . The company has confirmed that the information is also available on its official website.

Key Meeting Details

Auro Laboratories Limited has received credit rating assignments from Acuite Ratings & Research Limited for its bank facilities, as communicated to BSE Limited on April 14, 2026. The pharmaceutical company has been assigned ratings with a stable outlook across its banking arrangements.

Credit Rating Details

Acuite Ratings & Research Limited has assigned the following credit ratings to the company's bank facilities:

The ACUITE BB+ rating (read as ACUITE double B plus) applies to long-term facilities, while the ACUITE A4+ rating (read as ACUITE A four plus) covers short-term banking arrangements. Both ratings carry a stable outlook.

Rating Rationale and Company Strengths

The assigned ratings factor in several key strengths of Auro Laboratories Limited. The company benefits from extensive promoter experience, with Mr. Sharat Deorah and Mr. Siddhartha Deorah bringing long-standing expertise in the pharmaceutical and API manufacturing sector. The company has maintained an operational track record of over three decades in pharmaceutical and API manufacturing.

Auro Laboratories Limited operates with established relationships across its supply chain, including overseas vendors for key raw materials and customers across Europe and Southeast Asia. The company focuses on the anti-diabetic therapeutic segment and maintains a generic product base that serves as essential medicine with year-round global demand.

Recent Capacity Expansion and Financial Performance

The company has recently completed a significant brownfield expansion that impacted operations in FY2025. Revenue declined to Rs.19.40 crore in FY2025 compared with Rs.53.64 crore in FY2024, primarily due to the nine-month expansion period. With commissioning of the new block in August 2025, manufacturing capacity increased from 1,260 MT to 2,100 MT per year.

Revenue improved to Rs.22.25 crore in 9MFY2026, though this remained lower than expected due to geo-political situations in the middle east. The company reported operating margins of approximately 31% in 9MFY2026.

Rating Constraints and Risk Factors

The ratings are constrained by several factors including modest scale of operations where benefits of recently completed capex are yet to be fully achieved. The company operates with intensive working capital requirements, marked by high Gross Current Assets of 405 days in FY2025 compared to 199 days in FY2024.

The financial risk profile is moderate, with tangible net worth at Rs.42.97 crore as of March 31, 2025, compared to Rs.41.96 crore as of March 31, 2024. Gearing increased to 1.05 times from 0.63 times in FY2024 due to additional term loans for capacity expansion. The company also faces susceptibility to volatility in raw material prices and forex risk in the intensely competitive pharmaceutical industry.

Liquidity and Future Outlook

Acuite Ratings assessed the company's liquidity position as adequate, with net cash accruals of Rs.2.94 crore against maturing debt obligations of Rs.0.07 crore in FY2025. The company is expected to generate cash accruals in the range of Rs.6.00-15.00 crore during FY2026 to FY2027 against repayment obligations of Rs.2.00-6.00 crore during the same period.

The stable outlook reflects expectations that the company will continue to benefit from promoter experience and established customer relationships while managing the challenges associated with capacity utilization and working capital intensity.